Theravance Biopharma (TBPH) Corporate Presentation summary

Strategic focus and leadership

• Concentrates on respiratory and neurological diseases, with a strong financial base and cash-generating assets supporting near-term clinical catalysts.

• Leadership team has extensive experience from major biotech and pharmaceutical companies.

Ampreloxetine clinical and market opportunity

• Ampreloxetine is a first-in-class, once-daily selective norepinephrine reuptake inhibitor for symptomatic neurogenic orthostatic hypotension (nOH) in multiple system atrophy (MSA) patients.

• Phase 3 CYPRESS trial enrollment completed in Q3 2025; topline data expected Q1 2026, targeting ~40,000 underserved U.S. patients.

• Prior Phase 3 studies showed clinically meaningful and durable symptom improvement, with a 1.6-point benefit in OHSA composite score and no signal for worsening supine hypertension.

• Safety profile in MSA patients is comparable to placebo, with no significant increase in adverse events or supine hypertension.

• Ampreloxetine holds FDA Orphan Drug Designation and is positioned for a precision therapy launch in a concentrated treatment landscape.

YUPELRI performance and growth

• YUPELRI, the only once-daily nebulized LAMA for COPD, continues to generate strong cash flow and profit growth, with U.S. net sales of $71.4M in Q3 2025, up 15% year-over-year.

• Maintains a 35% U.S. profit share with Viatris and is eligible for tiered royalties in China; IP protection extends into 2039.

• Sizable addressable patient population remains, with ~1.9M U.S. COPD patients suitable for YUPELRI.

• Hospital initiation is a key driver, with over 80% of patients continuing therapy post-discharge.